Download PDF
CC BY 4.0 · Chinese medicine and natural products 2024; 04(01): e18-e23
DOI: 10.1055/s-0044-1782605
Review Article

Research Progress on the Treatment of Benign Prostatic Hyperplasia with Classical Prescriptions

Lin Zhang
1   Traditional Chinese Medicine (Zhongjing) School, Henan University of Chinese Medicine, Zhengzhou, Henan, China
,
Yang Wang
1   Traditional Chinese Medicine (Zhongjing) School, Henan University of Chinese Medicine, Zhengzhou, Henan, China
,
Mingze Liu
1   Traditional Chinese Medicine (Zhongjing) School, Henan University of Chinese Medicine, Zhengzhou, Henan, China
,
Zhenliang Wang
1   Traditional Chinese Medicine (Zhongjing) School, Henan University of Chinese Medicine, Zhengzhou, Henan, China
› Author Affiliations Funding This work was supported by the National Natural Science Foundation of China (81072716) and Zhengzhou Collaborative Innovation Special Project (2023XTCX049).
› Further Information
   Permissions and Reprints

Abstract

The main pathogenesis of benign prostatic hyperplasia (BPH) includes deficiency of healthy qi, blood stasis, and fluid retention. The root cause of BPH is the deficiency of healthy qi, for which Jingui Shenqi Pill and Zhenwu Decoction are used to nourish kidney qi and warm yang to promote diuresis. Blood stasis is the key pathogeneses of BPH, for which Guizhi Fuling Pill and Didang Decoction are used to dissipate blood stasis, relieve obstruction of orifices and facilitate bowel movement. Fluid retention is the most urgent symptom of BPH, for which Wuling Powder and Danggui Shaoyao Powder are used to transform qi and promote diuresis, addressing the urgent symptoms.

Keywords

benign prostatic hyperplasia - Jingui Shenqi Pill - Zhenwu Decoction - Guizhi Fuling Pill - Didang Decoction - Wuling Powder - Danggui Shaoyao Powder

CRediT Authorship Contribution Statement

Lin Zhang: Conceptualization, investigation, data curation, formal analysis, and writing original draft. Yang Wang: Date curation, formal analysis, and methodology. Mingze Liu: Writing-review and editing. Zhenliang Wang: Methodology, resources, supervision, project administration, writing-review, and editing.




Publication History

Received: 28 November 2023

Accepted: 10 January 2024

Article published online:
30 March 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Shen JW, Wang B, Lin S. et al. Advantages of Chinese medicine in treating dominant disease: benign prostatic hyperplasia. Zhongguo Shiyan Fangjixue Zazhi 2022; 8 (02) 220-226
    Google Scholar
  • 2 Sun ZX, Song CS, Xing JP. et al. Guidelines for the integrated diagnosis and treatment of benign prostatic hyperplasia using traditional Chinese and western medicine (trial version). Natl J Androl 2017; 3 (03) 280-285
    Google Scholar
  • 3 De NC, Albisinni S, Gacci M. et al. The role of inflammation in the progression of benign prostatic hyperplasia. Curr Bladder Dysfunct Rep 2013; 8 (02) 142-149
    CrossrefGoogle Scholar
  • 4 De Nunzio C, Kramer G, Marberger M. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60 (01) 106-117
    CrossrefPubMedGoogle Scholar
  • 5 Zhang CH, Li YQ, Pei XH. et al. Consensus of traditional Chinese medicine diagnosis and treatment for benign prostatic hyperplasia. Beijing J Tradit Chin Med 2016; 35 (11) 1076-1080
    Google Scholar
  • 6 Wang SZ, Wang B, Xu HS. et al. Professor Li Haisong's experience in treating benign prostatic hyperplasia based on the theory of blood stasis and qi deficiency in traditional Chinese medicine. Chin J Androl 2022; 8 (03) 105-108
    Google Scholar
  • 7 Peng W, Wu HX, Gui DW. et al. Evaluation of the clinical efficacy and safety of bipolar transurethral prostatectomy and traditional transurethral prostatectomy for treating benign prostatic hyperplasia. Chin J Human Sex 2017; 26 (05) 24-27
    Google Scholar
  • 8 Shen MX, Hu M, Shi JJ. et al. A comparison of diagnosis and medication strategies for patients with benign prostatic hyperplasia between urologists and geriatric physicians in China. Chin J Urol 2014; 35 (08) 601-605
    Google Scholar
  • 9 Xin SY, Ren XQ, Li LL. et al. Curative effect analysis of TURP for benign prostatic hyperplasia. Dalian Yike Daxue Xuebao 2018; 40 (06) 504-507
    Google Scholar
  • 10 Li Y, Ye M, Wang JQ. et al. Treatment and prevention of urethral stricture complicated by transurethral vapo-resection of prostate. Chin J Urol 2005; 26 (02) 121-124
    Google Scholar
  • 11 Xuan MY, Zhou BY, Ma DY. et al. Treating benign prostatic hyperplasia from the perspective of “weak spleen and stomach leads to obstruction of the nine orifices”. Global Tradit Chin Med 2022; 15 (05) 870-872
    Google Scholar
  • 12 Jia HL, Wang DM, Lu ZF. et al. Ye Pinliang's methods in diagnosing and treating benign prostatic hyperplasia with classic prescriptions. Hunan Jo Tradit Chin Med 2018; 34 (03) 43-45
    Google Scholar
  • 13 Zhao B, Li HS, Wang B. et al. Invigorating kidney and activating blood in the treatment of prostatic hyperplasia. Chin J Human Sex 2014; 23 (03) 52-54
    Google Scholar
  • 14 Dong BF, Li Q, Yuan ZJ. et al. Professor Qin Guozheng's experience in the treatment of benign prostatic hyperplasia. J Yunnan Univ Tradit Chin Med 2008; 31 (06) 30-32
    Google Scholar
  • 15 Chen RD, Yan X, Li XY. Professor Wang Qi's experience in the treatment of senile prostatic hyperplasia. J New Chin Med 2012; 44 (03) 148-150
    Google Scholar
  • 16 Yuan YF, Luo J, Zhu WX. et al. He Juqiao's Experience in treating benign prostate hyperplasia from the perspective of ” accumulation” theory. Guid J Tradit Chin Med Pharmacol 2020; 26 (10) 191-193
    Google Scholar
  • 17 Qi F. Treatment of Eurosclerosis caused by prostate hyperplasia with the method of removing blood stasis. Beijing J Tradit Chin Med 1998; 48 (01) 51-53
    Google Scholar
  • 18 Cheng WJ, Zhang MJ, Chen SZ. et al. Zhang Minjian's discussion on the diagnosis and treatment of benign prostate hyperplasia based on articles 71 and 125 of Shang Han Lun . Tradit Chin Med J 2021; 20 (05) 20-22
    Google Scholar
  • 19 Chen HF. Chinese External Medicine. Beijing: China Traditional Chinese Medicine Press; 2021: 297
    Google Scholar
  • 20 Shao WH, Zheng CF, Ge YC. et al. Age-related changes for the predictors of benign prostatic hyperplasia in Chinese men aged 40 years or older. Asian J Androl 2023; 25 (01) 132-136
    CrossrefPubMedGoogle Scholar
  • 21 Qi SW, Xiong CX, Lang XM. Exploration of Jinkui Shenqi Pill in the prevention and treatment of prostate hyperplasia. Clin J Tradit Chin Med 2004; 16 (05) 499-500
    Google Scholar
  • 22 Shou RG. Observation on the therapeutic effect of modified Jinkui Shenqi Pill on 122 cases of benign prostatic hyperplasia. Chin J Tradit Med Sci Technol 2010; 17 (05) 410
    Google Scholar
  • 23 Xu ZC, Zhang MJ, Su MY. et al. Clinical controlled research of Jinkui Shenqi pill in the treatment of patients with benign prostatic hyperplasia of Yang deficiency. Chin Med Pharmy 2021; 11 (13) 47-49 , 79
    Google Scholar
  • 24 Zhang XK, Wu D, Lu ZQ. The effect of the modified Jinkui Shenqi pill on serum sex hormones in rats with benign prostatic hyperplasia. Forum on Tradit Chin Med 2014; 29 (02) 52-54
    Google Scholar
  • 25 Shao B, Tian S, Wan S. Potential mechanism of Jinkui Shenqi Pill in treating benign prostatic hyperplasia based on network pharmacology. Chin Med J Res Prac 2022; 36 (06) 78-82
    Google Scholar
  • 26 Mao Y, Liang HH, Zhu JP. et al. Empirical analysis and modern research of Zhenwu decoction. Chin J Exp Tradit Med Formul 2020; 26 (01) 217-225
    Google Scholar
  • 27 Liu J. Treatment of elderly prostate hyperplasia with kidney qi deficiency type by combining Shenzhuo decoction and Zhenwu decoction. Shanxi J Tradit Chin Med 2014; 30 (02) 58
    Google Scholar
  • 28 Yao JJ, Zhang GN, Li SH. et al. Zhenwu decoction in treating 59 cases of acute urinary retention caused by prostatic hyperplasia. Shandong J Tradit Chin Med 2000; 19 (03) 154-155
    Google Scholar
  • 29 Yang KY, Chen DL. Observation on the treatment of 35 cases of lower urinary tract symptoms in elderly benign prostate hyperplasia with Zhenwu decoction. Forum Tradit Chin Med 2014; 29 (04) 8-9
    Google Scholar
  • 30 Li D. Clinical experience of Professor Wang Qi in treating benign prostatic hyperplasia. Chin J Tradit Chin Med Pharm 2011; 26 (02) 286-288
    Google Scholar
  • 31 Zhang CH, Li YF, Li YQ. Professor Li Yueqing's experience on benigh prostatic hyperplasia based on kidney deficiency and blood stasis. Mod Chin Clin Med 2018; 4 (03) 7-10
    Google Scholar
  • 32 Shen ZC, Xu XY, Cui Y. et al. Cui Yun's experience in treating benign prostate hyperplasia. Zhejiang J Tradit Chin Med 2021; 56 (08) 557-559
    Google Scholar
  • 33 Yang K, Yan F, Zhu Y. et al. Three cases of Zeng Qingqi's application of Guizhi Fuling pills in the treatment of andrology diseases. Shandong J Tradit Chin Med 2017; 3 (09) 811-812
    Google Scholar
  • 34 Ma JX, Chen WQ, Ding J. et al. Li Hai-song's eight methods in treating benign prostatic hyperplasia. Chin J Tradit Chin Med Pharm 2019; 34 (08) 3535-3537
    Google Scholar
  • 35 Dai XH. Guizhi Fuling pill in the treatment of benign prostate hyperplasia. Chin J Clin Physicians 2014; 43 (03) 80-82
    Google Scholar
  • 36 Zhang W, Song DR, Lin KL, Wang XX, Wei L, Xing J. [Literature research and status analysis on clinical application of Guizhi Fuling Formula]. Zhongguo Zhongyao Zazhi 2020; 45 (23) 5789-5796
    PubMedGoogle Scholar
  • 37 Peng SQ, Zhu LX, Cheng H. Clinical observation on the modified Guizhi Fuling pill in the treatment of 100 cases of benign prostatic hyperplasia. China Med Herald 2007; 4 (08) 115
    Google Scholar
  • 38 Jing MF, Feng XM. Observation on the therapeutic effect of modified Guizhi Fuling pills in treating 42 cases of benign prostatic hyperplasia. Inner Mongol J Tradit Chin Med 2016; 35 (08) 49
    Google Scholar
  • 39 Ding WL. Experimental Study on the Effects of modified Guizhi Fuling pill combined with Wuling powder on rats with BPH. Fujian: Fujian University of Traditional Chinese Medicine; 2012
    Google Scholar
  • 40 Yang AP, Liu H, Fan LX. et al. Study on mechanism of Guizhi Fuling pill in the treatment of benign prostatic hyperplasia based on network pharmacology. J Chin Medi Mater 2020; 43 (06) 1456-1461
    Google Scholar
  • 41 Wang XT, Hao L, Zhou XJ. et al. Study on the effects and mechanism of Guizhi Fuling Capsules on prostate hyperplasia model rats. Chin J Androl 2021; 35 (02) 31-35
    Google Scholar
  • 42 Wang F. Interpretation of Classic Prescriptions: How to Use Ancient Chinese Medicine Prescriptions. Beijing: People's Military Medical Publishing House; 2004: 384
    Google Scholar
  • 43 Yu JQ. Clinical experience of Ye Tianshi's application of the “insect-ant searching and clearing Bi syndrome method”. Liaoning J Tradit Chin Med 1982; 25 (03) 27-28
    Google Scholar
  • 44 Wei WH, Li GC. Treatment of 4 cases of prostatic hyperplasia with classical prescriptions. Henan Tradit Chin Med 2012; 32 (04) 414-415
    Google Scholar
  • 45 Hua G. Treatment of 40 cases of prostatic enlargement with supplemented Didang decoction. Shaanxi Tradit Chin Med 2004; 25 (12) 1087-1088
    Google Scholar
  • 46 Fan XZ. Treatment of 185 cases of benign prostatic hyperplasia with modified Didang decoction. Henan Tradit Chin Med 1999; 24 (06) 7
    Google Scholar
  • 47 Chang B, Li QF, Li CS. et al. Effect of Didang decoction medicated early to type 2 diabetic rats on serum IL-4 and IL-13 level and aorta TNF-αm RNA expression. J Sichuan Tradit Chin Med 2013; (03) 48-50
    Google Scholar
  • 48 Zhang JB. The Essentials of the Complete Works of Jingyue. Shenyang: Liaoning Science and Technology Press; 2007: 569
    Google Scholar
  • 49 Zhang KB, Li H, Wang SG. Mechanism of Wuling powder in treatment of benign prostatic hyperplasia based on network pharmacology and molecular docking technology. Acta Chin Med 2022; 37 (08) 1727-1733
    Google Scholar
  • 50 Yuan JX. Observation on the therapeutic effect of modified Wuling powder in treating 36 cases of benign prostatic hyperplasia with spleen qi failing to ascend and chronic urinary retention. J Fujian Univ Tradit Chin Med 2020; 51 (02) 89-90
    Google Scholar
  • 51 Yan MA. Observation on the therapeutic effect of Wuling Powder on 35 cases of benign prostatic hyperplasia with kidney yang deficiency. Chin J Gen Pract 2012; 10 (04) 583-584
    Google Scholar
  • 52 Liu SS, Wu ZY. Experimental study on the effects of Wuling Powder on the expression of collagen type I and III in the bladder detrusor muscle in benign prostatic hyperplasia. 2009 Zhejiang Provincial Academic Conference on Andrology and Urology; Hangzhou, China. 2009:78.
  • 53 Zhang YQ. Clinical study of treating benign prostatic hyperplasia with Chinese medicine in Japan. Foreign Med 2000; (03) 145-147
    Google Scholar
  • 54 Geng YC, Xu WL, Wang JX. Treatment of 60 cases of benign prostatic hyperplasia with modified Danggui Shaoyao powder formula. Mod J Integr Tradit Chin West Med 2003; 12 (08) 820-821
    Google Scholar
  • 55 Liu J, Shi Y, Zhu YD. et al. Clinical observation of Danggui Shaoyao powder and Wuling powder in the treatment of elderly patients with benign prostatic hyperplasia. Chin Community Doctors 2019; 35 (32) 106-107
    Google Scholar